Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum‐based treatment: A phase 1/2 trial

This phase 1/2 trial demonstrated that the combination of anlotinib and docetaxel significantly improved progression-free survival in patients with advanced nonsmall cell lung cancer after failure of…

Read the full article here

Related Articles